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Abstract
Introduction: Glucagon-like peptide-1 (GLP-1) attenuates the glycaemic response to small intestinal nutrient
infusion in stress-induced hyperglycaemia and reduces fasting glucose concentrations in critically ill patients with
type-2 diabetes. The objective of this study was to evaluate the effects of acute administration of GLP-1 on the
glycaemic response to small intestinal nutrient infusion in critically ill patients with pre-existing type-2 diabetes.
Methods: Eleven critically ill mechanically-ventilated patients with known type-2 diabetes received intravenous
infusions of GLP-1 (1.2 pmol/kg/minute) and placebo from t = 0 to 270 minutes on separate days in randomised
double-blind fashion. Between t = 30 to 270 minutes a liquid nutrient was infused intraduodenally at a rate of
1 kcal/min via a naso-enteric catheter. Blood glucose, serum insulin and C-peptide, and plasma glucagon were
measured. Data are mean ± SEM.
Results: GLP-1 attenuated the overall glycaemic response to nutrient (blood glucose AUC30-270 min: GLP-1 2,244 ±
184 vs. placebo 2,679 ± 233 mmol/l/minute; P = 0.02). Blood glucose was maintained at < 10 mmol/l in 6/11
patients when receiving GLP-1 and 4/11 with placebo. GLP-1 increased serum insulin at 270 minutes (GLP-1: 23.4 ±
6.7 vs. placebo: 16.4 ± 5.5 mU/l; P < 0.05), but had no effect on the change in plasma glucagon.
Conclusions: Exogenous GLP-1 in a dose of 1.2 pmol/kg/minute attenuates the glycaemic response to small
intestinal nutrient in critically ill patients with type-2 diabetes. Given the modest magnitude of the reduction in
glycaemia the effects of GLP-1 at higher doses and/or when administered in combination with insulin, warrant
evaluation in this group.
Trial registration: ANZCTR:ACTRN12610000185066
Introduction
The management of hyperglycaemia in the critically ill is
an important, and contentious, issue [1,2]. In critically ill
patients the ideal glycaemic range is uncertain, but is
likely to be ≤ 10 mmol/l [1]. When compared to criti-
cally ill patients with so-called ‘stress hyperglycaemia’
those with known diabetes are at greater risk of compli-
cations from hypoglycaemia, yet appear to be less
vulnerable to the toxicity of hyperglycaemia [2]. The
mechanisms underlying hyperglycaemia in critically ill
patients with known diabetes are complex, but include
relative insulin insufficiency, insulin resistance and
hyperglucagonaemia [3].
Glucagon-like peptide-1 (GLP-1), secreted from enter-
oendocrine L-cells in response to intestinal nutrient, has
the capacity to lower blood glucose [4]. In ambulant
type-2 diabetics, exogenous GLP-1 decreases blood glu-
cose via stimulation of insulin and suppression of gluca-
gon secretion, as well as slowing of gastric emptying [5].
As the effects of GLP-1 on insulin and glucagon are
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administration is low [6]. In ambulant type-2 diabetics
the GLP-1 analogue, exenatide, has been reported to
achieve comparable reductions in glycated haemoglobin,
but with less hypoglycaemia and a reduction in glycae-
mic variability when compared to insulin glargine [7].
For the above reasons GLP-1 is a potentially attractive
therapeutic option for the management of hyperglycae-
mia in the substantial number of critically ill patients
with pre-existing type-2 diabetes. This concept has been
strengthened by our recent reports that acute adminis-
tration of GLP-1 markedly attenuates the glycaemic
response to enteral nutrients in critically ill patients
with stress-hyperglycaemia [8,9].
The primary aim of this study was to evaluate the
effects of an acute, exogenous GLP-1 infusion (1.2 pmol/
kg/minute) on the glycaemic response to a postpyloric
nutrient infusion in critically ill patients with known
type-2 diabetes. Secondary aims were to explore mechan-
ism(s) underlying glucose-lowering if demonstrated, and
to determine whether glycaemic excursions could be lim-
ited to < 10 mmol/l with GLP-1 administration.
Materials and methods
Subjects
Critically ill adult patients known to have pre-existing
type-2 diabetes that were admitted to the Royal Adelaide
Hospital Intensive Care Unit between Jan 2009 and May
2010 were studied. Patients were included if aged
greater than 17 years and likely to remain mechanically
ventilated for > 48 hours. Exclusion criteria were preg-
nancy, contraindication to enteral feeding or post-
pyloric catheter insertion, acute pancreatitis and previous
surgery on the oesophagus, stomach or duodenum.
Subject demographic data are presented in Table 1. In
6 of the 11 subjects their diabetes was managed by diet
alone. Glycated haemoglobin ranged from 6.0 to 12.2%
and the body mass index (BMI) ranged from 20.2 to
50.2 kg/m
2. Admission diagnoses were categorised as
sepsis (n = 5), trauma (3), cardiac (2) and respiratory
(1). Nine patients had received exogenous insulin during
their admission prior to enrolment. The study was
approved by the Human Ethics Committee of the Royal
Adelaide Hospital and performed according to local
requirements for the conduct of research on uncon-
scious patients. Written, informed consent was obtained
from the next of kin.
Study protocol
The protocol is summarised in Figure 1. Patients were
studied over two consecutive days, in which they
received intravenous (IV) GLP-1 or placebo in a rando-
mised, double-blind fashion, as described previously [8].
In brief, a postpyloric feeding catheter was inserted
using an electromagnetic technique [10]. Enteral feeding
was ceased at least six hours and IV insulin ceased a
minimum of two hours before the commencement of
the study drug. Synthetic GLP-1-(7-36) amide acetate
(Bachem, Bubendorf, Germany) was reconstituted by the
Royal Adelaide Hospital Department of Pharmacy, as a
solution in 4% albumin and allocation concealment was
maintained throughout. Both GLP-1 (1.2 pmol/kg/min-
ute) and control (4% albumin) were infused at a rate of
1 ml/minute for 270 minutes [8]. At t = 30 minutes a
mixed nutrient liquid, Ensure
® (Abbott, Victoria,
Australia), was delivered into the small intestine con-
tinuously at a rate of 1.0 ml/minute for four hours (that
is, at 1 kcal/minute between t = 30 to 270 minutes).
Arterial blood samples were obtained immediately prior
to starting the IV (t = 0 minutes) and intraduodenal (t =
30 minutes) infusions and then at 15 minute intervals
for measurement of blood glucose [8]. Blood samples
were also collected at timed intervals for measurements
of serum insulin and C-peptide, as well as plasma gluca-
gon. If the recorded blood glucose was > 15 mmol/l the
IV infusion was ceased, insulin administered, and the
study terminated at that time.
Data analysis
Blood glucose was measured at the bedside using a porta-
ble glucometer [8]. Blood was collected for serum and
plasma as described previously [8]. Insulin was measured
by enzyme-linked immunosorbent assay (ELISA) (EZHI-
14K, Millpore, Billerica, MA, USA). The sensitivity of the
assay was 0.2 mU/L and the coefficient of variation was
6% within, and 10.3% between, assays. Serum C-peptide
was measured by ELISA (Immulite 2000 C-peptide,
Siemens Healthcare Diagnostics, Deerfield, IL, USA) and
the lower and upper analytical limits were 33 pmol/l and
6,620 pmol/l respectively. The intraassay coefficient of
variation was 4.8%. Plasma glucagon was measured by
radioimmunoassay (GL-32K, Millipore). The minimum
detectable limit was 20 pg/ml and maximum limit was
200 pg/ml, and the intra- and inter-assay coefficients of
variations were 3.9% and 5.5% respectively [11]. Free
Fatty Acids were measured by spectrophotometric deter-
mination using a Randox NEFA kit (FA115, Randox
Laboratories, Crumlin, County Antrim, UK). The sensitiv-
ity of the assay was 0.1 mmol/L and the inter-assay co-
efficient of variation was 4.7%.
Statistical analysis
Data are presented as mean ± SEM. Areas under curve
(AUC) were calculated using the trapezoidal rule. Power
calculations were performed using previous data [8] -
complete data were required in 10 subjects to detect an
absolute difference in the glycaemic response to nutrient
(that is, AUC30-270 min) of 345 mmol/l/minute at a
Deane et al. Critical Care 2011, 15:R35
http://ccforum.com/content/15/1/R35
Page 2 of 11two-sided alpha level of 0.05 with 80% power. In cases
in which the study was terminated because the blood
glucose was > 15 mmol/l the last glucose measurement
was used for all subsequent measurements, that is, ‘last
observation carried forward’ [12]. There was a trend for
baseline plasma glucagon concentrations to vary
between study days and, accordingly, glucagon is also
presented as Δ from the commencement of study drug
(that is, t = 0). Depending on normality the differences
between intervention and placebo were assessed using
Student’s paired t-test. Data were evaluated for potential
carry over effects. In addition to summary measure-
ments (AUC), individual time points at baseline (t = 0
minutes), prior to commencing feed (t = 30 minutes)
and study end (t = 270 minutes) were chosen ap r i o r i
for analysis [8]. The relationships between the magni-
tude of the change in blood glucose with glycated hae-
moglobin, Acute Physiology and Chronic Health
Evaluation (APACHE) II score, and baseline glucose
were evaluated using linear regression [13]. The null
hypothesis was rejected at the 0.05 significance. Statisti-
cal analyses were performed using SPSS (Version 16.0,
IBM, St Leonards NSW, Australia).
Results
Adverse gastrointestinal effects, such as nausea and/or
vomiting, were not evident during the study. The study
was terminated prematurely in three patients during pla-
cebo (patients number 5, 6 and 10 at 90, 120 and 150
minutes, respectively) and one patient receiving GLP-1
(patient 10 at 165 minutes) as blood glucose reached
the predetermined cut-off (> 15 mmol/l).
Blood glucose
Blood glucose concentrations are shown in Figure 2. At
the commencement of the intravenous infusion (t = 0
Table 1 Patient demographics, mean ± SEM
Age (years) 59 ± 5
Gender (Male : Female) 9:2
Body mass index (kg/m
2) 33 ± 3
Glycated haemoglobin (%) 8.5 ± 0.6
Anti-diabetic treatment prior to hospital admission (n) Metformin (2)
Sulfonyurea (2)
Insulin (1)
Dietary regimen (6)
Admission diagnosis (n) Sepsis (5)
Pneumonia (2)
Pyelonephritis
Influenza A (H1N1) virus
Septic shock from unknown focus
Trauma (3)
Isolated Chest (2)
Multi-trauma
Cardiac failure and/or cardiogenic shock (2)
Cardiogenic Pulmonary Oedema
Cardiogenic shock
Exacerbation of Chronic obstructive pulmonary disease (1)
APACHE II Score 21 ± 3
Admission 19 ± 3
First study day 6 ± 1
Days in ICU prior to first study day Exogenous catecholamines (3)
Medications (n) Exogenous steroids (2)
Exogenous catecholamines and steroids (2)
Acute renal impairment (n) *6
Acute hepatic impairment (n)** 2
* Acute renal impairment defined as serum creatinine > 150 umol/l, or rise in creatinine > 80 umol/l, or patient receiving renal replacement therapy when not on
chronic dialysis on first day of study.
** Acute hepatic impairment defined as patients with serum bilirubin > 24 umol/l, and alanine aminotransferase (ALT) > 55 U/l, and international normalised
ratio (INR) ≥ 1.3 on first day of study.
APACHE II, Acute Physiology and Chronic Health Evaluation II.
Deane et al. Critical Care 2011, 15:R35
http://ccforum.com/content/15/1/R35
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1 8.2 ± 0.7 vs. placebo 8.8 ± 0.9 mmol/l; P = 0.40).
Similarly, at the end of the ‘fasting’ period (t = 30 min-
utes) GLP-1 had no significant effect on blood glucose
(GLP-1 7.8 ± 0.6 vs. placebo 8.9 ± 0.9 mmol/l; P =
0.17). In response to nutrient infusion blood glucose
increased on both days (Δ glucose = 270 minutes - 0
minutes; P < 0.01 for both). GLP-1 reduced the peak
glycaemic excursion (GLP-1: 11.4 ± 0.9 vs. placebo 12.7
±1 . 1m m o l / l ;P = 0.04) and overall glycaemic response
to nutrient (AUC30-270 minutes: GLP-1: 2,244 ± 184 vs.
placebo: 2,679 ± 233 mmol/l/minute; P = 0.02). During
the small intestinal nutrient infusion glycaemia was
maintained at < 10 mmol/l in 6/11 patients receiving
GLP-1 and 4/11 patients during placebo. At study end
there was a reduction in glycaemia during GLP-1 (at t =
270 minutes: GLP-1: 11.1 ± 1.1 vs. placebo: 12.6 ± 1.2
mmol/l; P = 0.02).
Serum insulin
Serum insulin concentrations are shown in Figure 3.
During GLP-1 infusion an insulinotropic effect was evi-
dent (t = 0 minutes: 5.9 ± 1.7 mU/l vs. t = 270 minutes:
23.4 ± 6.7 mU/l; P = 0.02), while there was only a trend
for increased serum insulin during placebo (t = 0 min-
utes: 7.0 ± 1.5 vs. t = 270 minutes: 16.4 ± 5.5; P = 0.10).
At the commencement of the IV infusion and at the
end of the ‘fasting’ period GLP-1 had no effect on insu-
lin (at t = 0 minutes: GLP-1 5.9 ± 1.7 vs. placebo 7.0 ±
1.5 mU/l; P =0 . 3 0 ,a n da tt=3 0m i n u t e s :G L P - 1 :7 . 7±
2.4 vs. placebo: 6.4 ± 1.7 mU/l; P =0 . 3 5 ) .H o w e v e r ,a t
study end there was an increase in serum insulin during
GLP-1 when compared to placebo (at t = 270 minutes:
GLP-1: 23.4 ± 6.7 vs. placebo: 16.4 ± 5.5 mU/l;
P < 0.05). There was no difference in the insulin AUC0-
270 minutes (GLP-1: 3,076 ± 927 vs. placebo: 2,699 ± 787
mU/l/minute; P = 0.45).
Serum C-peptide
Serum C-peptide was greater than the maximum limit
in one patient during GLP-1 infusion and was recorded
as 6,620 pmol/l. Mean C-peptide concentrations are
shown in Figure 4. In response to nutrient infusion
there was an increment in C-peptide on both study days
((GLP-1 at t = 0 minutes 1,789 ± 689 vs. t = 270 min-
utes 3,227 ± 851 pmol/l.min; P = 0.02) and (placebo at
t = 0 minutes 1,793 ± 567 vs. 2,950 ± 845 pmol/l/min-
ute; P = 0.03)). At the predefined time-points, GLP-1
had no effect on serum C-peptide (at t = 0; GLP: 1,789
± 689 vs. placebo: 1,793 ± 567 pmol/l P = 0.98, at t =
30; GLP: 1,786 ± 642 vs. placebo: 1,779 ± 556 pmol/l;
P = 0.97, and at t = 270 GLP-1: 3,227 ± 851 vs. placebo:
2,950 ± 845 pmol/l; P = 0.38) and there was no affect
on AUC0-270 minutes (GLP: 6.29 vs. placebo 6.31 mmol/l/
minute; P = 0.97)
Plasma glucagon
Plasma glucagon concentrations are shown in Figure 5.
These were greater than the maximum detectable limit
throughout the study period during placebo in one
 
Time (minutes)
0*^+   15     30*^+ 45*^  60*^+          90*^+          120*^+        150*^+        180            210*^+         240            270^+
* Insulin blood sample
^ C-Peptide blood sample
+Glucagon blood sample
Blood glucose sample collected every 15 min from 0 to 270min
IV GLP-1 (1.2pmol/kg/min) or placebo infused t = 0 to 270mins 
Post pyloric nutrient liquid infused t = 30 to 270min at 1 Kcal/min
Figure 1 Time line. A randomised, double-blind, placebo-controlled, cross-over study with study drug infused for 30 minutes prior to
administration of small intestinal nutrient infusion.
Deane et al. Critical Care 2011, 15:R35
http://ccforum.com/content/15/1/R35
Page 4 of 11patient. Postprandial suppression of glucagon was not
observed during GLP-1 or placebo. There was a strong
trend for lower glucagon concentrations on the day of
GLP-1 administration, including baseline (at t = 0 min-
utes: GLP-1: 181 ± 24 vs. placebo: 219 ± 29 pmol/l; P =
0.06, at t = 30 minutes: GLP-1: 175 ± 21 vs. placebo:
214 ± 29: P = 0.06, and at t = 270 minutes: GLP-1: 184
± 32 vs. placebo: 212 ± 39; P = 0.11) so that plasma glu-
cagon was lower on the day of GLP-1 (AUC0-270 minutes;
P < 0.01). However, when data were evaluated as
changes from fasting concentration (Δglucagon)G L P - 1
had no effect Δglucagon (t = 30: GLP-1: -6.9 ± 8.2 vs. pla-
cebo: -5.8 ± 4.5; P = 0.89, and t = 270: GLP-1: -0.6 ±
10.9 vs. placebo -2.075 ± 17.4; P = 0.94). (Figure 6)
Serum non-esterified fatty acids
Serum non-esterified fatty acid (NEFA) concentrations
are shown in Figure 7. Fasting NEFA concentrations
were similar on both days (at t = 0 minutes: GLP-1:
0.66 ± 0.12 vs. placebo: 0.67 ± 0.14 mmol/l; P =0 . 9 3 ) .
The nutrient infusion had no effect on NEFA. GLP-1
did not have a detectable effect on fatty acids (at t = 30
minutes: GLP-1: 0.66 ± 0.14 vs. placebo: 0.68 ± 0.14
mmol/l; P = 0.82, at t = 270 minutes: GLP-1: 0.51 ±
0.19 vs. placebo: 0.59 ± 0.18; P = 0.44, and AUC0-270
minutes: GLP-1: 166 ± 40 vs. placebo: 187 ± 48 mmol/l/
minute; P = 0.21)
Relationships to glucose-lowering
When the glycaemic response to nutrient infusion was
greater, the magnitude of lowering that was observed
during GLP-1 IV infusion was also increased (r
2 =0 . 3 8 ;
P < 0.05) (that is, glucose-lowering was apparently
dependent on the blood glucose). There was a trend for
an association between the magnitude of glucose lower-
ing and the APACHE II on the first study day (r
2 =
0.31; P = 0.07). There was no association between glu-
cose-lowering and glycated haemoglobin or body mass
index (data not shown).
Discussion
Our major observation is that an acute exogenous
administration of GLP-1 (1.2 pmol/kg/minute) attenu-
ates the glycaemic response to small intestinal nutrient
Time (minutes)
Glucose 
(mmol/L) GLP-1
Placebo
Post pyloric nutrient liquid infused t = 30 to 270 min at 1 kcal/min
IV GLP-1 (1.2pmol/kg/min) or placebo infused t = 0 to 270min
**
* 14.0
13.0
12.0
11.0
10.0
9.0
8.0
7.0
6.0
0
0 30 60 90 120 150 180 210 240 270
Figure 2 Blood glucose. When compared to placebo glucagon-like peptide-1 (GLP-1) caused a reduction in blood glucose at the end of the
study (* at t = 270 minutes: GLP-1: 11.1 ± 1.1 vs. placebo: 12.6 ± 1.2; P = 0.02) and ameliorated glycaemia throughout the entire postpyloric
nutrient infusion (** AUC30 to 270 minute: GLP-1 2,244 ± 184 vs. placebo 2,679 ± 233 mmol/l/minute; P = 0.02).
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(mU/L)
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5
0
30
35
Time (minutes)
0 30 60 90 120 150 180 210 240 270
GLP-1
Placebo
Post pyloric nutrient liquid infused t = 30 to 270 min at 1 kcal/min
IV GLP-1 (1.2pmol/kg/min) or placebo infused  t = 0 to 270min
Figure 3 Serum insulin. When compared to placebo glucagon-like peptide-1 (GLP-1) caused an insulinotropic response (*** at t = 270 minutes:
GLP-1: 23.4 ± 6.7 vs. placebo: 16.4 ± 5.5 mU/l; P < 0.05).
0
1000
1500
2000
2500
3000
3500
4000
4500
0 30 60 90 120 150 180 210 240 270
Time (minutes)
C-Peptide 
(pmol/l)
GLP-1
Placebo
Post pyloric nutrient liquid infused t = 30 to 270 min at 1 kcal/min
IV GLP-1 (1.2pmol/kg/min) or placebo infused t = 0 to 270min
Figure 4 Serum C-peptide. When compared to placebo glucagon-like peptide-1 (GLP-1) caused no effect on C-peptide concentrations.
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Page 6 of 11infusion in critically ill patients with known type-2 dia-
betes. This effect is attributable, at least in part, to rela-
tive insulin stimulation. While the study establishes that
GLP-1 has the capacity to reduce glycaemia in this
group, during GLP-1 infusion glycaemic excursions were
limited to < 10 mmol/l in approximately 50% of
patients. There was evidence that the glucose-lowering
effect of GLP-1 was glucose-dependent (that is, the
greater the glucose concentrations during placebo, the
greater the reduction in glucose during GLP-1). Small
intestinal nutrient did not suppress glucagon in critically
ill patients with type-2 diabetes during either placebo or
GLP-1 infusion.
The dose of GLP-1 was selected based on previous
studies [8,9,13,14]. In ambulant type-2 diabetics, GLP-1
at higher doses (2.4 pmol/kg/minute) has a greater glu-
cose-lowering effect, but is also associated with
increased adverse effects, particularly nausea and vomit-
ing [15]. Such adverse effects may, potentially, be less
common in sedated patient receiving small intestinal
feeding, as opposed to nutrient administered orally to
alert subjects. In view of our observations the effects of
GLP-1 (or its analogues) at greater doses and/or in
combination with insulin merit evaluation [16,17]. The
feeding regimen was also based on our previous study
in which nutrient was administered via a postpyloric
tube [8]. Slowing of gastric emptying contributes to the
glucose-lowering effect of exogenous GLP-1 in health,
type-2 diabetics, and critically ill patients following an
intragastric ‘meal’ [9,18,19]. Accordingly, the magnitude
of the reduction in blood glucose is anticipated to be
greater during intragastric feeding, particularly in those
patients in whom gastric emptying is relatively normal.
The rate of small intestinal nutrient infusion (1 kcal/
minute) is less than optimal for maintaining nutritional
requirement in this group. However, based our previous
observations in non-diabetics [8], administering more
calories increased the likelihood of unacceptable hyper-
glycaemia during placebo. While gastric emptying is fre-
quently delayed in the critically ill, often markedly, [20]
and the rate of gastric emptying of nutrients in this
group may approximate 1 kcal/minute, in health the
rate is usually 1 to 4 kcal/minute [9]. As the relationship
between glycaemia and the rate of carbohydrate entry
into the small intestine is non-linear in health [21], it is
likely that a small intestinal feeding rate or gastric
0
140
160
180
200
220
240
260
280
Time (minutes)
0 30 60 90 120 150 180 210 240 270
Post pyloric nutrient liquid infused t = 30 to 270 min at 1 kcal/min
IV GLP-1 (1.2pmol/kg/min) or placebo infused t = 0 to 270min
Glucagon 
(pmol/l) GLP-1
Placebo
#
Figure 5 Plasma glucagon. When compared to placebo glucagon-like peptide-1 (GLP-1) caused a reduction in glucagon concentration AUC (#
P < 0.01) and strong trend to decreased glucagon concentrations at baseline, commencement of feeding and completion of study (P = 0.06, P
= 0.06 and P = 0.11 respectively).
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20
10
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-10
-20
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0 30 60 90 120 150 210 270 180 240
Time (minutes)
∆ Glucagon
 (pmol/L)
GLP-1
Placebo
Post pyloric nutrient liquid infused t = 30 to 270 min at 1 kcal/min
IV GLP-1 (1.2pmol/kg/min) or placebo infused t = 0 to 270min
Figure 6 Change in plasma glucagon. When compared to placebo glucagon-like peptide-1 (GLP-1) caused no apparent effect on change in
plasma glucagon concentrations from baseline.
0 30 60 90 120 150 180 210 240 270
0
0.2
0.4
0.6
0.8
1.0
Placebo
GLP-1
Time (minutes)
FFA
(mmol/L)
Post pyloric nutrient liquid infused t = 30 to 270min at 1 kcal/min
IV GLP-1 (1.2pmol/kg/min) or placebo infused t = 0 to 270min
Figure 7 Serum non-esterified fatty acids. When compared to placebo glucagon-like peptide-1 (GLP-1) caused comparable effects on NEFA.
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Page 8 of 11emptying > 1 kcal/minute will lead to greater glycaemic
excursions than observed in the current study. Other
limitations of this study should be recognised. No
reduction in fasting glycaemia was observed, probably
reflecting the short duration of fasting and GLP-1 infu-
sion (30 minutes) and the small cohort. Meier and col-
leagues have reported that fasting glycaemia is reduced
by GLP-1 in type-2 diabetics following major surgery
[14] and, in this study, pharmacological concentrations
may not have reached steady state until a significant
proportion of the fasting period had elapsed. The study
was ceased prematurely in one patient receiving GLP-1
as the blood glucose was > 15 mmol/l and in three
patients during placebo. When this occurred data were
estimated using the last observation carried forward
[11]. As the missing data occurred more frequently dur-
ing placebo, and this approach is likely to underestimate
the magnitude of the glycaemic excursion that would
have eventuated, any bias would likely to be in favour of
the null hypothesis. Given the outcome of studies relat-
ing to the effects of GLP-1 in ambulant type-2 patients
[22] it is perhaps surprising that GLP-1 did not normal-
ise blood glucose. This may be because the cohort com-
prised patients who were acutely ill - all patients
required mechanical ventilation (11/11), the majority
had a high APACHE II scores, approximately 50% (6/
11) had kidney failure, and approximately 30% (3/11)
were receiving vasoactive drugs during the study. The
maximal, or near-maximal, endogenous counter-regula-
tory hormonal response and administration of exogen-
ous catecholamines are likely to affect glucose tolerance
adversely and, may, attenuate the glucose-lowering effect
of GLP-1. Many patients admitted to the Intensive Care
Unit have less severe illnesses than those studied, and
the glucose-lowering effect of GLP-1 may, potentially,
be greater in this group. It would be useful to be able to
predict ‘GLP-1 responders’. Nauck and colleagues have
suggested that glucose-lowering induced by GLP-1 is
diminished in hospitalised patients receiving IV nutri-
tion that presented with acute pancreatitis, or had ele-
vated triglyceride concentrations or higher glycated
haemoglobin at baseline [13]. It is also likely that genetic
variation will determine response to GLP-1 [23]. We
were unable to determine which factors predicted glu-
cose-lowering in this small sample.
The mechanism(s) underlying the glucose-lowering
that occurs with GLP-1 in the critically ill are poorly
defined [24] and this issue represented a secondary aim
of this study. Serum insulin was increased markedly by
GLP-1, but the insulinotropic effect may have been
underestimated as the time between ceasing exogenous
insulin and starting the study drug was only two hours
which may have been insufficient for complete clearance
of exogenous insulin. This time period was chosen to
minimise the possibility of blood glucose concentrations
> 10 mmol/l prior to commencement of the study drug.
C-peptide, which is secreted in eqimolar concentrations
to insulin, was unaffected. However, approximately 50%
of the subjects had kidney failure, and metabolism of C-
peptide is impaired to a greater degree in this group
[24]. GLP-1 reduces fasting glucagon concentrations in
health, ambulant type-2 diabetics, and critically ill
patients with stress-hyperglycaemia [8,14,25-27] - and a
reduction in glucagon was anticipated [28], but GLP-1
h a dn oe f f e c to nΔglucagon in this study. While this may
suggest that hyperglucagonaemia in the critically ill dia-
betic patients is, relatively, resistant to suppression by
GLP-1, the substantial heterogeneity of the cohort stu-
died - in terms of pre-morbid conditions such as weight,
insulin resistance and glucose control (glycated haemo-
globin), as well as type and severity of acute illness -
may have confounded interpretation, particularly as the
sample size was relatively small. Loss of postprandial
glucagon suppression is characteristic of type-2 diabetes
[29]. To our knowledge this is the first report that glu-
cagon secretion is similarly unaffected by enteral nutri-
ent in type-2 diabetes who are critically ill. The lack of
any effect of GLP-1 on ‘postprandial’ glucagon is, how-
ever, surprising [25,28,30]. Non-esterified fatty acids
(NEFA) contribute to insulin resistance [28] and exo-
genous GLP-1 has been shown to have the capacity to
attenuate the postprandial increase in NEFA in other
groups [28,31]. In this study GLP-1 had no apparent
effect on lipidaemia, but, the small intestinal nutrient
infusion did not increase NEFA during placebo. Accord-
ingly, the lack of effect on NEFA may reflect the rate of
caloric delivery (1 kcal/minute) and increasing caloric
load could alter this result. It should also be noted that
glycaemia itself is a potent modulator of islet cell func-
tion and by not using a glycaemic clamp we may have
underestimated mechanisms underlying glucose-lower-
ing [13]. Other mediators that were not measured may
also have contributed to the glycaemic effect. For exam-
ple, in obese subjects the so-called ‘inactive’ GLP-1
metabolite (GLP-1(9-36)-NH2) has been reported to
markedly ameliorate hepatic glucose production inde-
pendent of its effects on islet cells, but concentrations of
the metabolite were not measured [32].
Conclusions
This study establishes that exogenous GLP-1 attenuates
the glycaemic response to enteral nutrient in critically ill
patients with type-2 diabetes. However, glycaemia was
maintained at < 10 mmol/l in only approximately 50%
of patients. Accordingly, the use of GLP-1 as a single
agent is unlikely to be an effective treatment unless
increased dose(s) have a greater effect and/or glucose-
lowering is markedly greater during intragastric feeding.
Deane et al. Critical Care 2011, 15:R35
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arguably, focus on critically ill patients with ‘stress
hyperglycaemia’ rather than those with pre-existing
type-2 diabetes. The effect of GLP-1 in other patient
groups who are less unwell (such as high dependency
care units or on discharge to general wards) also war-
rants evaluation.
Key messages
￿ Glucagon-like peptide-1 (GLP-1) decreases blood
glucose via stimulation of insulin, and suppression of
glucagon secretion, as well as slowing of gastric
emptying.
￿ The effects of GLP-1 on insulin and glucagon are
glucose-dependent, therefore, the risk of hypoglycae-
mia with its administration is low.
￿ In this study exogenous GLP-1 attenuates the gly-
caemic response to enteral nutrient in critically ill
patients with type-2 diabetes.
￿ However, the use of GLP-1 (at 1.2 pmol/kg/min-
ute) maintained glycaemia at < 10 mmol/l in only
approximately 50% of patients with pre-existing
type-2 diabetes.
￿ Further study with an increased dose, administra-
tion during intragastric feeding, and/or administra-
tion with insulin warrants evaluation.
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